Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new lens implant sharpen vision for nearsighted eyes?

NCT ID NCT07791381

Disease control Sponsor: Staar Surgical Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers are testing a new type of implantable lens, called an aspheric ICL, to correct or reduce nearsightedness (myopia) with or without astigmatism. The lens is placed inside the eye during surgery and is designed to improve vision. This small study will include 10 people aged 21 to 60 who are suitable candidates for ICL surgery. The main goal is to check the safety of the lens by tracking any adverse events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An implantable collamer lens (ICL) with an aspheric optic, a device placed inside the eye to correct or reduce nearsightedness and astigmatism.
What this could lead to
If the lens works well, it could offer a new option for people with myopia and astigmatism who want to reduce their dependence on glasses or contact lenses.
What could go wrong
This is a small, early proof-of-concept study with only 10 participants, so results may not apply to everyone. As with any eye surgery, there are risks of complications, and the lens may not fully correct vision.
Why investors are watching

STAAR Surgical is testing a new version of its implantable collamer lens, or ICL, in a small proof-of-concept study with 10 participants. The lens aims to correct or reduce nearsightedness with or without astigmatism. For a small company whose business depends on this lens technology, the readout matters because it could show whether the new optic design works as intended.

If it works: A positive result could support further development and eventual approval of the new lens, potentially expanding STAAR's product line. It might also strengthen confidence in the company's core technology among doctors and patients.

If it fails: The study is very small, so even a positive result may not predict success in larger trials. If the lens fails or the study is delayed, STAAR could face setbacks in its pipeline, and trials often fail at this early stage.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be between the age of 21 - 60 years, * Must be suitable for ICL surgery, * Must meet all unique study eligibility criteria Exclusion Criteria: * Outside the age of 21 - 60 years, * Not a suitable candidate for ICL surgery, * Does not meet all unique study eligibility criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Astigmatism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astigmatism myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Astigmatism Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.